loader2
Partner With Us NRI

Glenmark Life Sciences Ltd share Price Today

Company details

847.30
905.00
596.00
972.00
6M Return 1.73%
1Y Return 34.62%
Mkt Cap.(Cr) 10,423.37
Volume 371,753
Div Yield 2.64%
OI
-
OI Chg %
-
Volume 371,753

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Glenmark Life Sciences announced Q1FY25 results:

Financial Highlights:

  • For Q1FY25, GLS registered a revenue from operations of Rs 5,886 million, recording a growth of 9.7% QoQ and 1.8% YoY.
  • EBITDA for Q1FY25 was at Rs 1,650 million, a growth of 14.1% QoQ and EBITDA margins were at 28%, up 110 bps QoQ.
  • PAT for Q1FY25 was at Rs 1,115 million, a growth of 13.9% QoQ.
  • During Q1FY25, company generated strong free cash flow of Rs 1,213 million, leading to Cash and Cash Equivalents of Rs 4,263 million as of 30 June, 2024.

Business Highlights:

  • Generic business in Q1 FY25 grew by 10.5% QoQ and 6.2% YoY to Rs 5,354 million whereas CDMO business grew by 20.2% QoQ to Rs 425 million.
  • DMF / CEPs filing continue across major markets, taking the total cumulative filings to 532 as on 30 June 2024
  • In Q1FY25, Addition of 5 new products to the development grid, of which 3 products are High potent API (HP API) / Oncology class of drugs and 2 are synthetic small molecules. The HP API portfolio now extends to 20 products with an addressable market of USD 40 billion (Source: IQVIA, MAT Mar’24); 4 products are validated, and 4 products are in advanced stages of development.

Commenting on the company’s performance Yasir Rawjee, MD & CEO, Glenmark Life Sciences said, “We are pleased to report broad-based revenue growth for the quarter, where, as anticipated, growth has picked up sequentially. Our Generic API business experienced a robust 10.5% QoQ and 6.2% YoY growth. YoY growth was led by Europe, LATAM and RoW.

The GPL business saw a significant recovery this quarter. With the key drivers of our business - GPL, Non-GPL and CDMO performing well, we anticipate delivering steady growth with stable margins throughout FY25.”

Tushar Mistry, CFO, Glenmark Life Sciences said, “Q1FY25 has been marked by a recovery in growth. While gross margins were impacted by the discontinuation of the PLI benefit to GLS as well as product mix, employee costs have normalized, leading to stable EBITDA margins of 28% for Q1FY25. We are optimistic about maintaining the growth momentum for the rest of the year.

GLS generated strong cash flow of Rs. 121 crores during the quarter, further strengthening our debt-free balance sheet.”

Result PDF

View Other Company Results

Glenmark Life Sciences Ltd shares SWOT Analysis

Strengths (5)

  • Rising Net Cash Flow and Cash from Operating activity
  • Growth in Net Profit with increasing Profit Margin (QoQ)
  • Company with No Debt

Weakness (0)

Data not found

Opportunity (1)

  • Negative to Positive growth in Sales and Profit with Strong Price momentum

Threats (2)

  • Big Deal (Insider and SAST) sells last month greater than 1% of total shares
  • Increasing Trend in Non-Core Income

Resistance and support

R1 888.0
R2 925.4
R3 945.7
Pivot

867.67

S1 830.3
S2 810.0
S3 772.6
EMA SMA
859.7
850.8
827.1
771.8
870.6
852.2
823.4
766.6
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
SOCIETE GENERALE Block Purchase 2024-01-25 799.55 151173 BSE
BNP PARIBAS ARBITRAGE Block Sell 2024-01-25 799.55 151173 BSE
POLAR CAPITAL FUNDS PLC-HEALTHCARE OPPORTUNITIES FUND Bulk Purchase 2021-08-09 732.55 836000 NSE
Name Category Shares
NIRMA LIMITED PROMOTER 75%
GLENMARK PHARMACEUTICALS LIMITED PROMOTER 7.84%

OUR RESEARCH VIEW

Investment recommendation
GLS v2- Redefining growth under the new ownership …
Call Date
29 Apr 2024
Entry Price 806.00
Target Price 1,040.00
Duration
12-18 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Glenmark Life Sciences Ltd Stocks COMPARISON

Financials( in Cr) Glenmark Life Sciences Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 850.70 1,714.25 1,575.00 4,790.60 1,206.05
% Change -2.92 2.91 5 5.36 0.02
Mcap Cr 10,423.37 411,306.00 127,184.09 127,175.58 121,356.85
Revenue TTM Cr 2,161.22 48,496.85 15,790.60 7,845.00 19,547.40
Net Profit TTM Cr 466.96 9,648.44 2,513.47 1,600.00 3,854.40
PE TTM 23.32 41.15 28.67 79.37 31.45
1 Year Return 34.62 56.55 49.32 28.80 93.98
ROCE 29.86 17.20 14.76 16.41 23.94
ROE 22.28 16.13 10.66 12.15 20.64
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 2,138.21 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 3,555.27 41,445.87
LAST 3M 81,242.17 56,953.52
LAST 6M 176,360.83 56,552.99
LAST 12M 304,497.96 86,223.40
Glenmark Life Sciences Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Jul 26, 2024 l NSE Announcement

Board Meeting for Today

Jul 25, 2024 l Board Meetings for Today

NSE Board Meetings Forthcomming

Jul 25, 2024 l NSE Board Meetings Forthcomming

Date Action Type Ratio
Oct 17, 2023 Dividend 1125
Mar 24, 2023 Dividend 1050
Sep 15, 2022 Dividend 525

Glenmark Life Sciences Ltd Information

Stock PE (TTM)
23.32
Promoter Holding
82.85%
Book Value
190.3517
ROCE
29.86%
ROE
22.28%
Description
  • The company was incorporated as `Zorg Laboratories Private Limited`, a private limited company under the Companies Act, 1956 on 23 June 2011 at Pune and was granted the certificate of incorporation by the Registrar of Companies, Maharashtra at Pune ("RoC"). Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to `Glenmark Life Sciences Private Limited` pursuant to a special resolution passed by the shareholders of the Company on 25 July 2018 and a fresh certificate of incorporation dated 10 August 2018 was issued by the RoC. A shareholders` resolution was passed on 13 August 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited. The Company acquired API division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January 2019. The company is primarily engaged in the business of development,manufacture and marketing of Active Pharmaceutical Ingredients(APIs). The company`s R&D facilities are located at Mahape,Ankleshwar and Dahej and manufacturing facilities are located at Ankleshwar,Dahej,Mohol and Kurkumbh. During the year 2018-19, the company allotted 4,50,090 Equity Shares of Rs. 10/- each on the conversion of loan given to Director. During the year, 15,00,000 equity shares of the face value of Rs. 10 each fully paid-up issued to Glenmark Pharmaceuticals Limited (Parent Company) pursuant to the Preferential Allotment. Subsequent to the quarter ended 30 June 2021, the company has completed the IPO of 21,022,222 equity shares comprising a fresh issue of 14,722,222 equity shares and offer for sale of 6,300,000 equity shares of face value of Rs 2 each at premium of Rs 718 per share aggregating to Rs 15,136 million. Pursuant to the IPO, the equity shares of the Company are listed on BSE Limited and National Stock Exchange of India Limited with effect from 06 August 2021. The Gross Debt comprising of Outstanding Purchase Consideration payable to the Parent Company was Rs 8,008.3 million as on 09 July 2021.The Company has repaid the whole of this remaining outstanding purchase consideration from the proceeds of the Fresh Issue pursuant to the IPO.

Registered Address

Plot No. 170-172 Chandramouli, Industrial Est.Mohol Bazarpeth, Solapur, Maharashtra, 413213

Tel : 91-2189-234456/234246
Email : complianceofficer:glenmarklifesciences.com
Website : http://www.glenmarklifesciences.com
Registrar

KFin Techologies Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 543322
NSE Code : GLS
Book Closure Date (Month) : Sep
BSE Group : A
ISIN : INE03Q201024

FAQ’s on Glenmark Life Sciences Ltd Shares

You can buy Glenmark Life Sciences Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Glenmark Life Sciences Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jul 26, 2024 03:58 PM the closing price of Glenmark Life Sciences Ltd was Rs.850.70.

The latest PE ratio of Glenmark Life Sciences Ltd as of Jul 26, 2024 03:58 PM is 23.32

The latest PB ratio of Glenmark Life Sciences Ltd as of Jul 26, 2024 03:58 PM is 0.22

The 52-week high of Glenmark Life Sciences Ltd share price is Rs. 972.00 while the 52-week low is Rs. 596.00

According to analyst recommendations, Glenmark Life Sciences Ltd Share has a "Buy" rating for the long term.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jul 26, 2024 03:58 PM, the market cap of Glenmark Life Sciences Ltd stood at Rs. 10,423.37 Cr.

Download App

Download Our App

Play Store App Store
market app